Skip to main content

Multiple Myeloma

GEM-POMCIDEX Study: Treatment of Patients with RRMM Using Pomalidomide, Cyclophosphamide, and Dexamethasone (POMCIDEX)

Assessment of Options for Patients with RRMM with Triple-Class Exposure: Literature Review Indicates Urgent Need for New Treatments

Definition and Prediction of Unsustained Complete Remission in Patients with Transplant-Eligible MM

MRD Status Comparison by 3 Techniques in Patients with Newly Diagnosed Transplant-Eligible MM

Impact of Weight-Based Melphalan Dosing Strategies in Autologous Hematopoietic Stem-Cell Transplant for Multiple Myeloma

Erin K. Yeung, PharmD, BCPS; John Malamakal, PharmD, MS, BCPS, BCOP

Meeting Highlights

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

Meeting Highlights

Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma

Selecting Treatment for Relapsed/Refractory Multiple Myeloma in the Era of Multiple Choices

Meg Barbor, MPH

Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News

FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma

7
8
9
10
11

Page 10 of 11
Results 91 - 100 of 104